Gilead Sciences (NASDAQ:GILD) CFO Sells $432,690.00 in Stock

Key Points

• CFO Andrew Dickinson sold 3,000 shares on March 16 at an average price of $144.23 for a total of $432,690, reducing his stake by 1.65% to 179,191 shares (filed with the SEC).
• Gilead raised its quarterly dividend to $0.82 (annualized $3.28) with an ex-dividend date of March 13 and payment on March 30, implying a ~2.3% yield and a dividend payout ratio of 48.45%.
• Q4 results beat expectations (EPS $1.86 vs $1.83; revenue $7.93B vs $7.68B), Gilead set FY2026 guidance of $8.45–$8.85 EPS, and analysts hold a consensus "Moderate Buy" with a ~$157.62 price target.

Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CFO Andrew Dickinson sold 3,000 shares of the company's stock in a transaction on Monday, March 16th. The stock was sold at an average price of $144.23, for a total transaction of $432,690.00. Following the sale, the chief financial officer directly owned 179,191 shares of the company's stock, valued at approximately $25,844,717.93. This trade represents a 1.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Gilead Sciences Stock Down 0.6%

NASDAQ:GILD traded down $0.81 during mid-day trading on Tuesday, hitting $144.40. The company had a trading volume of 3,887,753 shares, compared to its average volume of 7,312,703. The business has a fifty day simple moving average of $141.16 and a 200-day simple moving average of $127.19. The firm has a market capitalization of $179.26 billion, a price-to-earnings ratio of 21.33, a PEG ratio of 1.90 and a beta of 0.36. Gilead Sciences, Inc. has a 1 year low of $93.37 and a 1 year high of $157.29. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.83 by $0.03. The business had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company's revenue was up 4.7% on a year-over-year basis. During the same period last year, the business posted $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Friday, March 13th. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.79. Gilead Sciences's dividend payout ratio (DPR) is 48.45%.

Wall Street Analysts Forecast Growth

GILD has been the subject of a number of analyst reports. TD Cowen upped their price objective on shares of Gilead Sciences from $145.00 to $160.00 and gave the company a "buy" rating in a research report on Wednesday, February 11th. Wells Fargo & Company lifted their target price on Gilead Sciences from $150.00 to $165.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 11th. Jefferies Financial Group began coverage on Gilead Sciences in a report on Tuesday, March 10th. They issued a "buy" rating and a $180.00 price target for the company. Leerink Partners raised their price objective on Gilead Sciences from $146.00 to $148.00 and gave the company an "outperform" rating in a research note on Wednesday, February 11th. Finally, Rothschild & Co Redburn lifted their price objective on Gilead Sciences from $159.00 to $170.00 and gave the stock a "buy" rating in a report on Tuesday, February 17th. Twenty-four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $157.62.

Institutional Investors Weigh In On Gilead Sciences

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Brighton Jones LLC lifted its holdings in Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock worth $1,326,000 after buying an additional 2,450 shares during the last quarter. Bison Wealth LLC bought a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $215,000. Sivia Capital Partners LLC increased its holdings in shares of Gilead Sciences by 16.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company's stock valued at $464,000 after acquiring an additional 602 shares during the last quarter. Creative Planning raised its position in shares of Gilead Sciences by 3.9% during the 2nd quarter. Creative Planning now owns 282,087 shares of the biopharmaceutical company's stock valued at $31,275,000 after acquiring an additional 10,533 shares in the last quarter. Finally, Cetera Investment Advisers lifted its stake in Gilead Sciences by 9.0% during the second quarter. Cetera Investment Advisers now owns 265,299 shares of the biopharmaceutical company's stock worth $29,414,000 after purchasing an additional 21,966 shares during the last quarter. Institutional investors own 83.67% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.